- Home
- MYGN vs AIOT Comparison
MYGN vs AIOT Comparison
Compare MYGN & AIOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- AIOT
- Stock Information
- Founded
- MYGN 1991
- AIOT 1993
- Country
- MYGN United States
- AIOT United States
- Employees
- MYGN N/A
- AIOT N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AIOT Telecommunications Equipment
- Sector
- MYGN Health Care
- AIOT Telecommunications
- Exchange
- MYGN Nasdaq
- AIOT Nasdaq
- Market Cap
- MYGN 642.0M
- AIOT 594.8M
- IPO Year
- MYGN 1995
- AIOT N/A
- Fundamental
- Price
- MYGN $8.33
- AIOT $5.46
- Analyst Decision
- MYGN Hold
- AIOT Strong Buy
- Analyst Count
- MYGN 13
- AIOT 4
- Target Price
- MYGN $13.50
- AIOT $10.50
- AVG Volume (30 Days)
- MYGN 959.5K
- AIOT 1.5M
- Earning Date
- MYGN 11-04-2025
- AIOT 11-11-2025
- Dividend Yield
- MYGN N/A
- AIOT N/A
- EPS Growth
- MYGN N/A
- AIOT N/A
- EPS
- MYGN N/A
- AIOT N/A
- Revenue
- MYGN $832,900,000.00
- AIOT $391,206,000.00
- Revenue This Year
- MYGN $0.06
- AIOT $21.83
- Revenue Next Year
- MYGN $5.68
- AIOT $10.13
- P/E Ratio
- MYGN N/A
- AIOT N/A
- Revenue Growth
- MYGN 3.83
- AIOT 119.82
- 52 Week Low
- MYGN $3.76
- AIOT $3.70
- 52 Week High
- MYGN $22.92
- AIOT $8.71
- Technical
- Relative Strength Index (RSI)
- MYGN 64.16
- AIOT 56.15
- Support Level
- MYGN $7.68
- AIOT $5.02
- Resistance Level
- MYGN $8.25
- AIOT $5.66
- Average True Range (ATR)
- MYGN 0.38
- AIOT 0.26
- MACD
- MYGN -0.01
- AIOT -0.01
- Stochastic Oscillator
- MYGN 78.80
- AIOT 80.20
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About AIOT PowerFleet Inc. Common Stock
PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.